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Gruetter, Rolf, Elizabeth R. Seaquist, and Kaˆmil
Ugurbil. A mathematical model of compartmentalized neu-
rotransmitter metabolism in the human brain. Am J Physiol
Endocrinol Metab 281: E100–E112, 2001.—After adminis-
tration of enriched [1-13C]glucose, the rate of 13C label incor-
poration into glutamate C4, C3, and C2, glutamine C4, C3,
and C2, and aspartate C2 and C3 was simultaneously mea-
sured in six normal subjects by 13C NMR at 4 Tesla in 45-ml
volumes encompassing the visual cortex. The resulting eight
time courses were simultaneously fitted to a mathematical
model. The rate of (neuronal) tricarboxylic acid cycle flux
(VPDH), 0.57 6 0.06 mmol zg
21 zmin21, was comparable to the
exchange rate between (mitochondrial) 2-oxoglutarate and
(cytosolic) glutamate (Vx, 0.57 6 0.19 mmol zg
21 zmin21),
which may reflect to a large extent malate-aspartate shuttle
activity. At rest, oxidative glucose consumption [CMRGlc(ox)]
was 0.41 6 0.03 mmol zg21 zmin21, and (glial) pyruvate car-
boxylation (VPC) was 0.09 6 0.02 mmol zg
21 zmin21. The flux
through glutamine synthetase (Vsyn) was 0.26 6 0.06
mmol zg21 zmin21. A fraction of Vsyn was attributed to be from
(neuronal) glutamate, and the corresponding rate of appar-
ent glutamatergic neurotransmission (VNT) was 0.17 6 0.05
mmol zg21 zmin21. The ratio [VNT/CMRGlc(ox)] was 0.41 6 0.14
and thus clearly different from a 1:1 stoichiometry, consis-
tent with a significant fraction (;90%) of ATP generated in
astrocytes being oxidative. The study underlines the impor-
tance of assumptions made in modeling 13C labeling data in
brain.
nuclear magnetic resonance; glutamate; neurotransmission;
in vivo spectroscopy
IN THE TRADITIONAL CONTEXT of neuroscience, the brain’s
tasks are mainly accomplished by the neurons, with
the surrounding glial cells performing simple, passive
tasks of maintaining the milieu required for optimal
neurotransmission. However, the glial cells are more
than just passive components in neuronal function, in
that they are intimately involved in the process of
neurotransmission through glial uptake of glutamate
(Glu) from the synaptic cleft (64, 77, 78). Glu is the
major excitatory neurotransmitter (62); it is present in
the mammalian brain in high concentrations and is
dynamically stored in presynaptic vesicles (73). De-
spite the high intracellular concentration of Glu, the
extracellular concentration must be maintained very
low (;0.004 mM) to avoid excitotoxicity. Presynaptic
release of Glu into the synaptic cleft therefore requires
efficient uptake mechanisms, which are achieved by
Glu transporters (2). Most of the metabolic evidence
suggests that uptake by glia is the most important
process. Most of the Glu is in neurons (51), as is most of
the glutaminase activity (52), whereas astrocytes con-
tain most of the glutamine (Gln) (51), all of the glu-
tamine synthetase (42), and pyruvate carboxylase (63);
they predominantly take up and metabolize acetate
(74). Early studies showed that cerebral Glu metabo-
lism is compartmentalized, involving two major meta-
bolic pools of Glu (7, 16, 71). The large pool has been
associated with the neuronal compartment and the
small pool with the glial compartment. Recent studies
have again supported the participation of glia in neu-
rotransmission through rapid clearance of Glu from
the synaptic cleft into neighboring glia, on the basis of
conductance currents associated with Glu uptake (6)
and consequent metabolism. The uptake of Glu into the
astrocytes is associated with uptake of glucose into the
glial compartment (39), thereby linking stimulated en-
ergy metabolism between glial and neuronal cells dur-
ing neurotransmission.
In summary, the glial-neuronal metabolic relation-
ship mediated by Glu-Gln interconversion appears to
be essential for glutamatergic neurotransmission. This
compartmentation of metabolic pathways into both the
glial and neuronal fractions extends to other systems
as well and may represent a fundamentally important
biochemical process for cerebral tissue. For instance,
aspartate-like immunoreactivity was recently found to
colocalize with Glu in brain slices (25), and aspartate
aminotransferase stained the neuronal compartment
most intensely (75).
In recent years, 13C NMR spectroscopy of brain slices
(4), extracts (37, 64), and cell cultures (9, 26, 46) has
corroborated and extended the initial findings of com-
partmentalized cerebral energy and Glu metabolism.
Given the specific compartmentation of critical en-
zymes for cerebral energy metabolism, the use of 13C
NMR spectroscopy offers an unprecedented amount of
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highly specific information (17). Such data are obtained
from the amount of label incorporated into the differ-
ent positions of one or more molecules after adminis-
tration of a specifically labeled metabolic precursor,
such as glucose, the major source of energy in brain (3,
5, 57, 68). From the specific labeling pattern, the rela-
tive and absolute fluxes through a given pathway can
be calculated. For example, the incorporation of multi-
ply labeled glucose into multiply labeled Glu at the C2
position is indicative of pyruvate carboxylase flux at
low enrichment (37). The specific information gained
by 13C NMR spectroscopy can also be used to estimate
rates of pyruvate recycling and of malic enzyme activ-
ity (17, 47). In addition to the analysis of isotopomers
(33, 40), which has been in widespread use for analyz-
ing 13C NMR spectra of brain extracts (68), dynamic
incorporation of label into a given position can be
observed. Metabolic rates can be quantitatively ex-
tracted from the rate of label incorporation. These
approaches require by necessity that accurate tempo-
ral data be obtained in vivo, but the derivation of
metabolic rates depends more critically on the specific
model used to analyze the data and the assumptions
made (76). In brain, several models have been pro-
posed, some of which have been used to calculate met-
abolic rates (17, 23, 44, 67, 72). Given the compart-
mentation of cerebral enzymes, such as glutamine
synthetase, the landmark observation that Gln label-
ing can be detected noninvasively in the brain (19, 21,
23) is thus of crucial importance to the study of meta-
bolic compartmentation, as pointed out in a recent
review (3).
The aim of this study was to fully incorporate the
maximum information achievable in in vivo localized
13C NMR spectra of human brain using state-of-the-art
sensitivity and methodology (20) available at 4 Tesla.
The resulting measurement of label incorporation into
eight distinct resonances in amino acids was predicted
to provide metabolic rates that are less dependent on
each other. Overall, on the basis of known cellular
compartmentation of metabolism and enzymes, we
sought to determine whether sufficiently specific infor-
mation could be obtained from the human brain to
permit assessment of cellular cerebral energy metabo-
lism in vivo. This information can then be used further
to serve as a basis for unraveling the relative contri-
butions of both cell types to brain function in health
and disease.
MATERIALS AND METHODS
Subjects. Six healthy human subjects were studied after
giving informed consent according to procedures approved by
the Institutional Review Board: Human Subjects Committee.
On the morning of study, subjects reported to the Center for
Magnetic Resonance Research (University of Minnesota) in
the fasting state. In preparation for the clamp procedure, an
intravenous catheter was placed antegrade in each forearm
and retrograde in a lower leg/foot. Arms and legs were
warmed by placing preheated pads and water-soaked towels
around the lower extremities. Somatostatin was infused into
one arm vein at a progressively increasing rate up to 0.16
mg zkg21 zmin21 to suppress endogenous pancreatic insulin
and glucagon secretion (61). Dextrose (50% wt/vol D-glucose)
was infused into the other arm vein at a variable rate ad-
justed to maintain target glycemia at 15 mM plasma glucose
concentration. The infusion procedures have been described
previously (23). Alterations in the glucose infusion rate were
made on the basis of plasma glucose concentration measured
on a nearby glucose analyzer (Beckman, Fullerton, CA) in
blood samples taken from the foot vein every 3–5 min (60).
Additional blood samples were obtained every 20 min for the
later determination of plasma insulin concentration, and
both before and after the study for assessment of plasma
ketone levels. When the subject was ready for spectroscopic
study, a bolus injection of 30 g of [1-13C]glucose was given as
50% D-glucose in water, with a fractional enrichment of 99%
over 1–2 min. As in our previous study (23), the plasma
glucose was then clamped at the peak level of glycemia (;15
mM plasma glucose concentration) by the infusion of 10 g
[1-13C]glucose (prepared as 20% D-glucose in water with a
fractional enrichment of 70%) at a variable rate determined
by the plasma glucose concentrations. After administration
of [1-13C]glucose, additional plasma samples were collected
every 10 min to be used for the determination of plasma
glucose enrichment by use of gas chromatography-mass spec-
trometry (GC-MS).
Chemical assays and GC-MS. Insulin was measured in
serum that had been frozen within 30 min of acquisition with
the double-antibody method of Morgan and Lazarow (50).
Plasma insulin was not detected in our study. Absence of
serum ketones was verified in the clinical laboratory by a
qualitative test based on the nitroferrocyanide reaction.
Analyses of the 13C enrichment in serum glucose were
performed by the University of Minnesota General Clinical
Research Center GC/MS Core Laboratory by use of the fol-
lowing standard procedures. After deproteinization, the su-
pernatants were purified by chromatography, as previously
described (8). The fraction containing glucose was converted
to the pentatrimethylsilyl O-methyloxime derivative by a
modification of the procedure of Laine and Sweeley (35).
After the trimethylsilyl derivative was produced, analysis by
GC-MS was performed on a Hewlett-Packard 5973 MSD
system equipped with an HP6890 series gas chromatograph
in the selective ion-monitoring mode. Ions at 160 and 161
were analyzed to determine the enrichment of 13C in carbon
1 of glucose.
13C MR spectroscopy. All studies used a 4-Tesla magnet
with a 125-cm bore, equipped with a standard clinical body
gradient coil and amplifier (Siemens AS25, Erlangen, Ger-
many). The magnet and gradient system was interfaced with
a spectrometer console (Varian, Palo Alto, CA) by use of a
manufacturer-supplied interface board. Subjects were posi-
tioned supine on the patient bed above the surface coil. After
coil tuning, MR imaging was performed to determine local-
ization for spectroscopy according to anatomical landmarks.
Subjects wore earplugs to minimize gradient noise and were
placed into the coil holder with cushions to minimize head
movement. Shimming of the identified region of interest was
performed using FASTMAP (19), which resulted in water
linewidths of 7–9 Hz.
To efficiently separate the proton (169 MHz) and the 13C
frequency (42.5 MHz), we used a three-coil design in which
the circular polarized 1H radio frequency (RF) field was
generated by two distinct 14-cm-diameter coils driven by a
quadrature hybrid. The 13C coil was a single-loop 9-cm-
diameter surface coil. This three-coil design was recently
described elsewhere (1). Observation of the Federal Drug
Administration guidelines for power absorption was verified
using methods and procedures presented in detail elsewhere
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(1, 20, 23). RF power for excitation, polarization transfer, and
decoupling was carefully calibrated using a small sphere
containing 0.5 ml of 13C-labeled formic acid placed at the 13C
coil center, as described previously (for example, see Ref. 20).
These calibrations were used to ensure proper power settings
for decoupling as well as to minimize RF power needed for
the experiment.
Localization was performed on the longitudinal proton
z-magnetization, which was transferred to the 13C magneti-
zation using a semi-adiabatic polarization transfer method,
PRoton Excited Carbon-13 Image SElected in vivo Localized
spectroscopY, or PRECISELY (20), as described recently (23).
Editing delays were set to correspond to a heteronuclear
coupling constant of JCH 5 137 Hz.
Spectra were analyzed after 3-Hz apodization, zero-filling,
and fast-Fourier transform by use of the fitting algorithm
supplied by the spectrometer software. To reduce variability,
linewidths of 13C-13C doublets were set to the linewidth of
the corresponding center peak, and the fitted frequencies of
the 13C-13C doublets were fixed to be symmetrical to the main
resonance, according to the homonuclear 13C-13C coupling
constants. After correction for field frequency drift, the fre-
quencies and linewidths of the fitted peaks were determined
on the basis of fit to a spectrum representing the average of
$60 min of data accumulation. This procedure was justified
on the basis of the observation of ,3-Hz changes in 1H
spectra (corresponding to ,0.75-Hz changes in 13C spectra)
in studies performed over similar time periods with the
identical equipment. Convergence of the fit procedure was
verified by inspecting the residuals of the fit point by point.
Quantification of integrated 13C signals was performed
relative to the signals of N-acetyl-aspartate (NAA) at 22.7
(C6) and 54.0 ppm (C2) set to correspond to 0.12 mM on the
basis of our previous observation of a stable NAA C2 signal at
54.0 ppm (23). Stability of the NAA signals was verified for
2 h after start of the [1-13C]glucose infusion for both the C2
and C6 resonances (data not shown). This calculation as-
sumes that the 1H saturation factors are identical in vivo,
which was supported by inversion-recovery nulled spectros-
copy at 4 Tesla (49) and the relatively long repetition time of
3 s. Signal differences due to differential T2 were neglected,
because the measured linewidths of 2–3 Hz implied that T2 is
longer than 100 ms, which is much longer than the T2
evolution time of the sequence (9 ms).
Modeling of compartmentalized neurotransmitter metabo-
lism in the human brain. The time courses were used as the
experimental data to fit the model recently proposed in Ref.
23, which is redrawn in Fig. 1A. Because the scheme does not
explicitly describe the mechanisms by which label is scram-
bled in the tricarboxylic acid (TCA) cycle, we have added the
scheme in Fig. 1B.
The scheme in Fig. 1B explicitly accounts for potential
finite exchange between the amino acids in the cytosol and
the TCA cycle intermediates in the mitochondrion. The dif-
ferential Eqs. 5–21 that follow are derived by the generalized
procedure described in Ref. 23. Label scrambling in the
amino acids due to TCA cycle activity was modeled according
to the scheme in Fig. 1B, derived as a special case of the
general model by Chance et al. (10).
Briefly, label derived from the C1 or C6 of glucose arrives
at the C3 of pyruvate/lactate, where depending on whether
the label enters the TCA cycle via pyruvate carboxylase (flux
VPC) or pyruvate dehydrogenase (VPDH) reaction, it ulti-
mately is detected in the C4 or C2 position of Glu. Label
scrambling due to TCA cycle activity results in the C2 and C3
of 2-oxoglutarate (OG) receiving label from the C4 of OG (Fig.
1B). In neurons, VPC was neglected, and in astrocytes, con-
servation of mass required that the flux through glial pyru-
vate dehydrogenase be equal or larger than VPC, which was
modeled by setting the flux through glial pyruvate dehydro-
genase to VPC 1 Vg, with Vg $ 0 (Fig. 1A), where Vg accounts
for the difference in flux between glial pyruvate dehydroge-
nase and pyruvate carboxylase.
Fig. 1. A: proposed model of cerebral compartmentation based on
published enzymatic compartmentation in the brain. Left: glial com-
partment; right: neuronal compartment. This figure is adapted from
one in Ref. 23, with the following abbreviations for metabolic fluxes:
CMRGlc, glucose consumption; VPDH, neuronal tricarboxylic acid
(TCA) cycle; VPC, rate of pyruvate carboxylase; Vg1VPC, glial pyru-
vate dehydrogenase 1 VPC; Vx, exchange between cytosolic amino
acids and mitochondrial TCA cycle intermediates; Vsyn, glutamine
synthetase; VNT, apparent rate of glutamate neurotransmission;
Vefflux, loss of glutamine (Gln) from the glial compartment; Vout,
VLout, label dilution and exchange of lactate across the blood-brain
barrier; Vgase, glutaminase rate; V NT
app, rate of Gln flux from the
astrocyte to the glutamatergic neuron. Also, Lac3/Pyr, C3 of lactate
and pyruvate; OAA2,3, C2 & C3 of oxaloacetate; OG2,3,4, C2, 3, & 4 of
2-oxoglutarate (OG). B: scheme illustrating label scrambling from
[1-13C]glucose due to activity of the TCA cycle. Label transfer from
OG C3 to OAA C2 at the succinate level is modeled by the bidirec-
tional arrow between OAA C3 and OG C3. Note also the distribution
of label including flux through pyruvate carboxylase and pyruvate
dehydrogenase and the relationship with cytosolic amino acids. Vx
denotes the exchange between mitochondrial TCA cycle intermedi-
ates and cytosolic amino acids. In neurons, VPC 5 0, and in glia,
Aspartate (Asp) was assumed to be negligible. Boldface indicates
NMR-measurable molecules and respective positions.
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Label accumulation into Gln proceeds almost exclusively
in glia because of the exclusive localization of glutamine
synthetase (EC 6.3.1.2) in astrocytes (Fig. 1A).
The effect of a sizable brain glucose concentration on the
isotope kinetics cannot be completely ignored (22, 43). There-
fore, we calculated the enrichment of brain glucose from the
measurements of plasma glucose concentration and isotopic
fraction by use of the reversible Michaelis-Menten model of
glucose transport, which has been shown to provide a more
consistent depiction of brain glucose concentrations and
transport (12, 24). The differential equation describing the
change in total brain glucose [Gbrain(t)] and in
13C-labeled
brain glucose [13Gbrain(t)] is given by
dGbrain
dt
5 Tmax
Gplasma~t!
Kt 1 Gbrain~t!/Vd 1 Gplasma~t!
2 Tmax
Gbrain~t!
Vd[Kt 1 Gplasma~t!] 1 Gbrain~t!
2 CMRGlc
(1)
d13Gbrain
dt
5 Tmax
13Gplasma~t!
Kt1Gbrain~t!/Vd1Gplasma~t!
2 Tmax
13Gbrain(t)
Vd[Kt1Gplasma~t!] 1 Gbrain(t)
2 CMRGlc
13Gbrain~t!
Gbrain~t!
(2)
where Kt is the Michaelis-Menten constant of glucose trans-
port, Tmax is the corresponding maximal transport rate, and
CMRGlc is glucose consumption. For a more detailed descrip-
tion see Ref. 24. Brain glucose is metabolized by glycolysis to
pyruvate, which is assumed to be in rapid exchange with
lactate, given the high activity of cerebral L-lactate dehydro-
genase (EC 1.1.1.27). We assumed cerebral lactate to have
the same isotopic enrichment in both cell types because of the
small lactate concentration and large distribution volume
(55), in agreement with a high lactate transport efficiency
(47). Therefore, only one single cerebral rate of glucose con-
sumption was taken into account; this, however, does not
assume that all glycolysis occurs in glia.
The rate of label incorporation into cerebral lactate is thus
a function of changing fractional enrichment of brain glucose
and the metabolic rate CMRGlc and the dilution/efflux Vout
(29)
d13Lac3
dt
5 CMRGlc
13Glc1~t!
Glc~t!
1 CMRGlc
13Glc6~t!
Glc~t!
2 ~2 CMRGlc(ox) 1 Vout!
13Lac3~t!
Lac
1 VLoutFELac
(3)
This equation assumes that Vout models the exchange of label
with unlabeled plasma lactate, whose fractional enrichment
is given by FELac, which was assumed to be 0.011 in this
study. CMRGlc was set to 0.45 mmol g
21 min21, and oxidative
CMRGlc [CMRGlc(ox)] was set to 0.97 CMRGlc. Equations 1–3
were solved using a fourth-order Runge-Kutta algorithm
based on the measured time course of plasma glucose and its
fractional enrichment, yielding the time course of fractional
enrichment for lactate C3, Lac3(t)/Lac.
Vout is assumed to be equivalent to label dilution due to
pentose phosphate shunt activity and label dilution at the
lactate level (32) and, in principle, also at the acetyl-CoA
level. Because the brain relies almost entirely on glucose for
energy metabolism, and because fatty acid uptake is small
and ketone bodies were not detected in our study, we as-
sumed that dilution at the acetyl-CoA level in brain is
negligible. Net loss of lactate can be modeled by assuming
VLout # Vout. In the resting brain, VLout ; Vout, or al-
most complete oxidative metabolism of glucose, defined as
2 CMRGlc 5 2 CMRGlc(ox) 2 VLout 1 Vout.
In our scheme (Fig. 1A), total CMRGlc(ox) (defined as the
rate of glucose equivalents entering the TCA cycle) is related
to the fluxes in glial and neuronal TCA cycles by the rela-
tionship
CMRGlc(ox) 5
VPDH 1 Vg
2
1 VPC (4)
where Vg denotes the flux through glial pyruvate dehydroge-
nase corresponding to complete oxidation of pyruvate, i.e., Vg
1 VPC is the total flux through glial pyruvate dehydrogenase
(as outlined in the scheme in Fig. 1A), VPDH is the analogous
flux in neurons, and VPC is the rate of net oxaloacetate (OAA)
and net citrate formation (anaplerosis). The net carbon com-
pound formed is in our steady-state model removed by net
consumption of OG and biosynthesis of Gln.
Throughout this section, the superscript 13 denotes the
13C label, and the numeral subscripts indicate the position at
which the label is observed, e.g., 13Glu4 denotes the sum of all
isotopomers of Glu with 13C label at the C4 position. The
derivation of these and the following differential equations
follows from tracer kinetics and is mathematically equivalent
to the procedure outlined previously (23) and used in many
earlier studies (10, 14, 40, 57).
Because the gluconeogenic capacity, as well as the capacity
to generate pyruvate or lactate from amino acids, is generally
small in the neuronal compartment (38), we assumed that
the net flux of Glu carbon skeletons into the neuronal TCA
cycle was negligible compared with VPDH.
The NMR signal represents total tissue Glu concentration,
(and Gln, conversely) of which the vesicular neurotransmit-
ter pool is generally viewed to constitute a small fraction.
Neglecting the contribution of extracellular Glu (0.004
mmol/g) to the NMR signal, the neuronal Glu pool [Glu(n)] can
be partitioned into a vesicular (small) neurotransmitter sig-
nal GluNT plus a metabolic pool Glumet. Based on studies
showing 1) rapid redistribution of label between vesicular
and extravesicular Glu (73), 2) that isolation of Glu-contain-
ing vesicles requires rapid isolation procedures (58), and 3)
that influx of Glu results in simultaneous efflux of Gln from
glial cells (34, 48), we assumed that the exchange between
Glumet and GluNT is rapid compared with VNT
app, the rate of Gln
flux from the astrocyte to the glutamatergic neuron. For
definitions of symbols, see also Fig. 1A. In this case, the label
incorporation into the observed Glu signal will reflect the
label incorporation into the neurotransmitter Glu pool,
GluNT.
The lack of metabolic pathways branching off at the level
of neuronal Gln, or Gln(n), and the metabolic steady-state
requirement that no net concentration changes occur, e.g.,
dGln(n)/dt 5 0, imply that the rate across the glial-neuronal
interface be VNT
app. Under these assumptions, the rate of uni-
directional Glu transport out of the neuron is equal to VNT
app,
and the rate of OG and 13Glu4
(n) labeling can be written,
accordingly, as
d13OG4
~n!
dt
5 VPDH
13Lac3~t!
Lac
2 ~VPDH 1 Vx!
13OG4
~n!~t!
OG(n)
1 Vx
13Glu4
~n!~t!
Glu(n)
(5)
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d13Glu4
~n!
dt
5 Vx
13OG4
~n!~t!
OG(n)
2 ~Vx 1 VNT
app!
13Glu4
~n!~t!
Glu(n)
1 VNT
app
13Gln4
~n!~t!
Gln(n)
(6)
d13OG3
~n!
dt
5 VPDH
13OAA2
~n!~t!
OAA(n)
2 ~VPDH 1 Vx!
13OG3
~n!~t!
OG(n)
1 Vx
13Glu3
~n!~t!
Glu(n)
(7)
d 13Glu3
~n!
dt
5 Vx
13OG3
~n!~t!
OG(n)
2 (Vx1VNT
app)
13Glu3
~n!~t!
Glu(n)
1 VNT
app
13Gln3
~n!~t!
Gln(n)
(8)
By equating the forward and backward exchange rates be-
tween Glu and OG, we have assumed that net flux of neuro-
nal Glu into the neuronal TCA cycle is negligible compared
with the unidirectional exchange rates (Vx) that describe the
exchange rate between (mitochondrial) OG and (cytosolic)
Glu (see also Fig. 1). Therefore, Vx is a composite figure that
describes the combined effect of glutamate dehydrogenase,
aspartate transaminase, and transport across the mitochon-
drial membranes. Given the slow incorporation of nitrogen
into Glu compared with the glutamine amide group (15),
glutamate dehydrogenase flux must be small compared with
the flux through glutamine synthetase; it was, therefore,
neglected. This assumption is also consistent with studies
showing a reduced Glu concentration when aspartate
transaminase was inhibited (11). The differential equations
for Glu3 are equivalent to those for Glu4 and are simply
derived by replacing the subscript. Likewise, analog equa-
tions can be written for Glu2 simply by replacing the sub-
script. Label incorporation into OAA, which is in exchange
with Asp, is described by the following equations
d13OAA3
~n!
dt
5
VPDH
2
13OG4
~n!~t! 1 13OG3
~n!~t!
OG(n)
2 ~VPDH 1 Vx!
13OAA3
~n!~t!
OAA(n)
1 Vx
13Asp 3
(n)~t!
Asp(n)
(9)
d13OAA2
~n!
dt
5
VPDH
2
13OG4
~n!~t!
OG(n)
2 ~VPDH 1 Vx!
13OAA2
~n!~t!
OAA(n)
1
VPDH
2
13OG3
~n!~t)
OG(n)
1 Vx
13Asp2
~n!~t!
Asp(n)
(10)
d13Asp3
~n!
dt
5 Vx
13OAA3
~n!~t!
OAA(n)
2 Vx
13Asp3
~n!~t!
Asp(n)
(11)
d13Asp2
~n!
dt
5 Vx
13OAA2
~n!~t!
OAA(n)
2 Vx
13Asp2
~n!~t!
Asp(n)
(12)
The lack of metabolic pathways branching off at neuronal
Gln was based on observation of little or no Gln efflux into the
medium of cultured neurons, as shown in, for example, Ref.
38. The rate of change in 13Gln4
(n) is thus given by
d13Gln4
~n!
dt
5 VNT
app
13Gln4
~g!~t!
Gln(g)
2 VNT
app
13Gln4
~n!~t!
Gln(n)
(13)
and likewise for the other positions in Gln(n), because the
glutaminase reaction does not change the positional 13C
labeling between Gln and Glu.
Glial metabolism: glutamine synthetase and pyruvate car-
boxylase. In reference to the majority of evidence that links
the Glu/Gln interrelationship to excitatory neurotransmis-
sion (77), we have denoted the rate from Gln(n) to Glu(n) and
from Glu(n) to Glu(g) as VNT
app, the apparent rate of neurotrans-
mission. In view of the low glutaminase (EC 3.5.1.2) activity
in glia (28), we assumed that the glutaminase rate (Vgase) is
negligible compared with VNT
app. Although we assumed in this
study that Vgase 5 0 (as indicated by the dashed arrow in Fig.
1A), the equations below are written to allow for some Vgase.
The steady-state requirement
Vsyn 5 VPC 1 Vgase 1 VNT
app
assumes that anaplerosis leads to glial loss of Gln. Loss of
Gln from the glial cell to the extracellular space is, in this
case, modeled by the term Vefflux 5 VPC. The rate of
13Gln4
(g)
labeling is thus given by
d13Gln4
~g!
dt
5 Vsyn
13Glu4
~g!~t!
Glu(g)
2 ~Vgase 1 Vefflux 1 VNT
app!
13Gln4
~g!~t!
Gln(g)
(14)
and equivalent equations can be written for the 2 and 3
positions of glial Gln simply by replacing the subscript 4 with
2 and 3, respectively
d13Gln3
~g!
dt
5 Vsyn
13Glu3
~g!~t!
Glu(g)
2 ~Vgase 1 Vefflux 1 VNT
app!
13Gln3
~g!~t!
Gln(g)
(15)
d13Gln2
~g!
dt
5 Vsyn
13Glu2
~g!~t!
Glu(g)
2 ~Vgase 1 Vefflux 1 VNT
app!
13Gln2
~g!~t!
Gln(g)
(16)
In addition to label derived from neuronal Glu(n), label can be
incorporated into glial glutamate [Glu(g)] from the glial TCA
cycle, the rate of which is given by Vg (Fig. 1). Pyruvate
carboxylase (PC, EC 6.4.1.1) transfers label from pyruvate
C3 to OAA C3 in the glial compartment. In this model,
reverse flux from OAA to fumarate was neglected, on the
basis of previous reports suggesting a substantial difference
in labeling at the C1 and C4 position of OAA (31), which is
supported by differential labeling of Glu C2 and C3 in astro-
cytes (41). Neglecting any backflux to fumarate underesti-
mates the pyruvate carboxylase flux when assessed from the
differential labeling of the C2 and C3 positions in Glu and
Gln. Given the small pool size of cerebral OAA and most TCA
cycle intermediates, label equilibration is assumed to be
relatively fast until it reaches OG. The small pool size of glial
Glu(g) relative to the high activity of the malate-aspartate
shuttle is assumed to result in rapid label equilibration of
Glu(g) relative to OAA(g). Glu2
(g) is also labeled from neuronal
Glu2
(n) as well as from glial Glu4
(g) on subsequent turns of the
TCA cycle.
The rate of lactate labeling is calculated as described in
Eq. 3 and set to that of pyruvate, which is the label precursor
for acetyl-CoA; thus
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d13OG4
~g!
dt
5 ~Vg 1 VPC!
13Lac3~t!
Lac
2 ~Vg 1 VPC 1 Vx!
13OG4
~g!~t!
OG(g)
1 Vx
13Glu4
~g!~t!
Glu(g)
(17)
d13Glu4
~g!
dt
5 Vx
13OG4
~g!~t!
OG(g)
2 (Vx 1 Vsyn)
13Glu4
~g!~t!
Glu(g)
1 Vgase
13Gln4
~g!~t!
Gln(g)
1 VNT
app
13Gln4
~n!~t!
Glu(n)
(18)
d13OAA2
~g!
dt
5
Vg
2
13OG4
~g!~t! 1 13OG3
~g!~t!
OG(g)
2 Vg
13OAA2
~g!~t)
OAA(g)
(19)
d13OAA3
~g!
dt
5 VPC
13Lac3~t!
Lac
1
Vg
2
13OG4
~g!~t!
OG(g)
2 ~Vg 1 VPC!
13OAA3
~g!~t!
OAA(g)
1
Vg
2
13OG3
~g!~t!
OG(g)
(20)
d13OG3
~g!
dt
5 ~Vg 1 VPC!
13OAA2
~g!~t!
OAA(g)
2 (Vg 1 VPC 1 Vx)
13OG3
~g!~t!
OG(g)
1 Vx
13Glu3
~g!~t!
Glu(g)
(21)
Numerical procedures. The cerebral Glu(g) 1 Glu(n) pool
size labeled by [13C]glucose was estimated at 5.7 mmol/g, in
agreement with previous studies (53, 54, 56), from the
amount of 13C-labeled Glu signal divided by the fractional
enrichment determined from the 13C-13C isotopomers as de-
scribed previously (21, 37, 40). Likewise, the cerebral aspar-
tate pool was estimated at 1.5 mmol/g, and this neurotrans-
mitter was assumed to be mainly in the neuronal
compartment.
The set of differential equations (see Eqs. 5–21) was
solved, and 13[Glu(n)1Glu(g)]2,3,4 and
13[Gln(n)1Gln(g)]2,3,4
were simultaneously fitted using commercially available soft-
ware (SAAM II, The SAAM Institute, Seattle, WA) to the
separately measured time courses of Glu C4 and Gln C4 as
well as the C2 and C3 positions. In addition, we included the
combined signal of Asp C2 and C3 in the modeling, Asp23,
because the smaller pool size of Asp makes the labeling curve
less dependent on the exchange Vx compared with the rate of
OAA labeling.
All metabolite pools [except for cerebral glucose (Glcbrain)]
were assumed to be constant during the duration of the
[13C]glucose infusions: 14% of the total glutamate pool was
assumed to be in the glial compartment; see Ref. 17 and
references therein. Consistent with most evidence (51), we
assumed that the neuronal Gln, Gln(n), was small (e.g., 0.2
mmol/g), and we verified that this assumption did not influ-
ence substantially the labeling time course of Gln. The glu-
tamine pool, Gln(n) 1 Gln(g), turned over by [13C]glucose
metabolism, was estimated at 1.7 mmol/g with the same
methods as for Glu. We assumed cerebral OG and OAA pools
to be very small, i.e., OG(n) 5 OG(g) 5 OAA(n) 5 OAA(g) 5 0.1
mmol/g. The cerebral lactate pool was set to a fixed value of
1.0 mmol/g. The pool sizes of other glycolytic and TCA cycle
intermediates were also assumed to be small and without
effect on isotope kinetics; they were validated to be without
effect on the conclusions of this paper up to a total mass of
several micromoles per gram. On the basis of our inability to
detect signals from TCA cycle intermediates, even when
summing spectra over extended measurement periods from
all measured subjects, we assumed the pool sizes to be below
0.05 mmol/g, which we verified to have a negligible impact on
the calculated fluxes (not shown).
The following rates were varied to achieve the best fit to
the data: VPDH, Vx, Vout, VNT, Vg, VPC. All fluxes were
constrained to be positive in the fitting process. To take into
account that the malate-aspartate shuttle is the major mech-
anism by which the brain maintains the cytosolic redox state
under normoxic conditions, we constrained the exchange rate
Vx to be equal or greater than the pyruvate dehydrogenase
flux, VPDH.
RESULTS
The improved sensitivity achieved at 4 Tesla was
used to reduce the volume of interest being investi-
gated and to achieve localization to a metabolically
more homogenous area in the human brain. Figure 2
illustrates the excellent sensitivity achieved with our
approach. The spectrum was acquired 1 h after the
start of [1-13C]glucose infusion and represents data
collection corresponding to 45 min from a volume of 45
ml. In addition to the three dominant resonances from
Glu, resolved peaks were detected from the correspond-
ing three positions in Gln, and resonances from NAA
and GABA were routinely observed. Furthermore, the
resolution and sensitivity afforded the simultaneous
Fig. 2. 13C NMR detection of label incorporation into cytosolic amino acids in a 45-ml volume in the human
occipital lobe at 4 Tesla. This is a representative spectrum obtained from a 3 3 3 3 5-cm3 volume in the human
visual cortex in 45 min. Resonance assignments are as follows: Glu C2 at 55.6 ppm, Gln C2 at 55.0 ppm,
N-acetyl-aspartate (NAA) C2 at 54.0 ppm, Asp C2 at 53.7 ppm, NAA C3 at 40.5 ppm, GABA C4 at 40.45 ppm, Asp
C3 at 37.6 ppm, GABA C2 at 35.3 ppm, Glu C4 at 34.2 ppm, Gln C4 at 31.7 ppm, Glu C3 at 28.0 ppm, and Gln C3
at 27.7 ppm. In addition to these resonances, those ascribed to the homonuclear 13C-13C coupling were readily
detected at positions of all Glu resonances (brackets). The spectrum was processed with a mild Lorentz-to-Gauss
apodization (3 Hz) and is shown without baseline correction.
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detection of the homonuclear isotopomers in all three
Glu resonances, C2, C3, and C4.
The spectral data shown in Fig. 2 exemplifies the
spectral resolution and suppression of extraneous lipid
signal achieved in our study. The resonance intensity
for Glu C2, C3, C4 and Gln C2, C3, C4, as well as Asp
C2 and C3, was determined with a temporal resolution
of 15 min, resulting in eight simultaneously recorded
time courses of label incorporation into cytosolic amino
acids. To improve sensitivity, the labeling curves for
aspartate C2 and C3 were averaged and accordingly
fitted. Intersubject reproducibility of 13C label incorpo-
ration was evaluated from the standard deviation,
which was on average 0.1 mmol/g.
One major goal of this study was to assess the rate of
label exchange between the cytosolic amino acids and
their mitochondrial TCA cycle counterparts. This ex-
change is mediated by the malate-aspartate shuttle
(Fig. 3A), which provides a mechanism by which Asp
and Glu can be labeled from the TCA cycle through
transport of Asp and Glu by the Asp/Glu antiporter (11,
36). On the basis of this mechanism, we analyzed the
exchange between Asp and OAA as well as between
Glu and OG with a single reaction rate, Vx. The use of
the label incorporation into the amino acids ideally
assumes that the rate of label incorporation into the
cytosolic amino acids is a good approximation of label
incorporation into the metabolic counterpart, e.g., OG
in the mitochondrion. However, as stated previously,
this assumption generally is true only when the ex-
change between OG and Glu is fast compared with the
TCA cycle flux (45). In addition, as shown in Fig. 3B,
the accuracy by which the amino acid represents the
label incorporation into the TCA cycle intermediate
also depends on the relative pool sizes. For example,
Asp, whose concentration is at least three times less
than that of Glu, much more closely represents the
fractional enrichment of OAA (dotted curves in Fig. 3B)
at an otherwise equal relative rate Vx/VPDH, whereas
Glu labeling is a much poorer indicator of the corre-
sponding OG labeling (solid curves in Fig. 3B). The
effect of assuming widely varying Vx had a quantita-
tively negligible impact on calculating the TCA cycle
flux from the measurement of Asp C21C3 (Asp23)
alone (second column in Table 1). On the other hand,
the measurement from Glu C4 (Glu4) alone illustrates
a more profound effect of the assumed value of Vx on
the derived TCA cycle flux, as shown in the third
column of Table 1.
The model proposed in Ref. 23 and shown in the
scheme in Fig. 1A was fitted to the curves showing
label incorporation into Glu C4, C3, and C2 as well as
Gln C2, C3, and C4 and Asp C2 and C3 (Fig. 4). The fits
resulted in a covariance matrix whose normalized off-
diagonal elements were in magnitude ,0.6 for all but
one element. The resulting fitted fluxes are shown in
Table 2, along with the normalized covariance matrix
in Table 3. Because glucose is the dominant fuel for
generation of energy in brain, the fitting was con-
strained, in that Vx was not allowed below the mini-
mum required flux by the malate-aspartate shuttle,
Fig. 3. A: fluxes participating in the malate-aspartate shuttle
(adapted from Stryer). The overall flux between mitochondrial OG/
OAA and cytosolic Asp/Glu is modeled by Vx. B: to illustrate that the
pool size does affect the fidelity by which the corresponding amino
acid reflects the rate of labeling of its corresponding TCA cycle
intermediate, the label in Asp relative to OAA (dotted curves) was
compared with the label in Glu C4 relative to OG C4 (solid curves) for
Vx 5 5.7 and 0.55 mmol zg
21 zmin21, assuming VPDH 5 0.7
mmol zg21 zmin21. Concentrations of the participating amino acids
were assumed in this simulation to be 5.7 mmol/g for Glu and 1.5
mmol/g for Asp.
Table 1. TCA cycle flux as a function of rate
of exchange, measured from Asp C21C3 and Glu C4
Asp23 Glu4
Vx557 mmol zg
21 zmin21* 1.04 0.53
Vx510 mmol zg
21 zmin21 1.04 0.55
Vx52 mmol zg
21 zmin21 1.03 0.65
Vx51 mmol zg
21 zmin21 1.01 0.83
Vx50.75 mmol zg
21 zmin21 1.00 1.00
Tricarboxylic acid (TCA) cycle flux (VPDH) as a function of the
exchange rate (Vx) measured from the C2 and C3 of aspartate (Asp23)
and the C4 of glutamate (Glu4). VPDH is obtained by fitting the flux
of dilution/efflux and that of pyruvate dehydrogenase, but keeping
other fluxes fixed at values reported in Table 2 and dividing them by
VPDH obtained at Vx 5 0.75 mmol zg
21 zmin21. *Value previously
published in Ref. 45.
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which was assumed to be VPDH, where the fitting
process converged.
Provided that flux through glutamine synthetase is
exclusively due to the flux from neuronal Glu(n), Gln
should be equally labeled relative to Glu at each carbon
atom. Table 4 shows the relative amount of 13C NMR
signal at the C2, C3, and C4 positions determined
60–120 min after the start of the glucose infusion,
which was found to be measurably higher at the C2
compared with the C3 and C4 positions (P , 0.01). In
addition to the different isotopomer populations in Gln
relative to Glu, fitting to the label incorporation curves
also indicated a substantial contribution of pyruvate
carboxylase to the total flux through glutamine syn-
thetase.
DISCUSSION
In the present study we have for the first time
comprehensively measured and analyzed multiple
curves of label incorporation into resonances from
three different amino acids in the human brain. The
inclusion of the amino acid Asp with a much lower
concentration than Glu helped to reduce the mathe-
matical covariance between fitted fluxes compared
with that present in previous studies (45, 76), as
judged from Table 3 and Fig. 3B. Even higher sensitiv-
ity can be obtained, for example by higher static field
strength (such as 7 Tesla) and by increasing the frac-
tional enrichment of the amino acids through the use of
multiply labeled glucose, e.g., [1,6-13C2]glucose. It
should then be possible to achieve much more robust
measures of TCA cycle flux than through the measure-
ment from Glu alone, as suggested by the comparisons
presented in Fig. 3B and Table 1. Nevertheless, some of
the advances presented in this study were achieved on
the basis of the improved sensitivity afforded by the
use of a human 4-Tesla system. The sensitivity shown
in Fig. 2 obtained from a 45-ml volume in 45 min is
comparable to that of a 144-ml volume at 2.1 Tesla in
60 min (65). This illustrates the substantial gain in
sensitivity (approximately threefold) achieved at 4
Tesla compared with 2.1 Tesla. The reduced volume
size measured in this study currently is the smallest
reported for this type of experiment. Thus partial vol-
ume effects were smaller because of a higher contribu-
tion of gray matter to the overall signal. In addition to
the size, the location of the voxel assured that signals
were acquired predominantly from gray matter, con-
sistent with the very high cerebral blood flow and the
high metabolic glucose consumption rate measured by
fluorodeoxyglucose and [11C]glucose positron emission
tomography (PET) in this region (70). Furthermore, 1H
MRS (59) consistently showed a choline-to-creatine ra-
tio associated with a predominantly gray matter com-
position of the human occipital lobe (unpublished
data), according to Hetherington et al. (27). We there-
fore assumed that interindividual differences in tissue
composition were minimized for the volumes used in
the present study.
Our study indicates a rate of neuronal TCA cycle flux
(VPDH, Fig. 1A) of 0.57 mmol zg
21 zmin21 (Table 2). The
small but measurable glial pyruvate dehydrogenase
flux, VPC 1 Vg, is consistent with active glial metabo-
lism of acetate (74). Incorporating the small glial TCA
cycle flux rate of 0.06 mmol zg21 zmin21 and the rate of
pyruvate carboxylase, VPC, of 0.09 mmol zg
21 zmin21, an
oxidative glucose consumption rate [CMRGlc(ox)] of
0.41 6 0.03 mmol zg21 zmin21 was derived, which is in
excellent agreement with PET measurements of total
CMRGlc in resting gray matter (70) and the nearly
complete oxidation of cerebral glucose under resting
conditions.
Fig. 4. Observed rates of label incorporation into the main amino
acids Glu, Gln, and Asp. Lines represent the best fit of model shown
schematically in Fig. 1A.
Table 2. Derived metabolic fluxes
VPDH Vx CMRGlc(ox) VNT VPC Vg Vout Vsyn
0.5760.06 0.5760.19 0.4160.03 0.1760.05 0.0960.02 0.0660.04 0.4160.04 0.2660.06
Metabolic fluxes (mmol zg21 zmin21) with reference to model shown in Fig. 1A; see definitions of fluxes in legend to Fig. 1.
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In principle, the metabolic relationship between Glu
and Gln implies that the relative distribution of label
in the different positions of Gln must be the same as
that of Glu, with the assumption that the large (neu-
ronal) pool is the dominant source of label for the (glial)
pool of Gln. Any differential extent of labeling in brain
Gln therefore implies that other, glial, reactions, such
as pyruvate carboxylase, must contribute significantly
to the flux through glutamine synthetase. In this in-
vestigation, we extended our previous work to measure
pyruvate carboxylase activity in the human brain by
use of a single, isotopically enriched substrate that can
be obtained at comparatively low cost, namely D-[1-
13C]glucose. Our measurement is in excellent agree-
ment with previous studies using D-[U-13C6]glucose
(37) and our previous report from larger volumes in the
human brain (23). The 95% confidence interval for the
rate of pyruvate carboxylation in this and our previous
study (23) overlaps well with the upper limit of a more
recent study, which assessed the rate of anaplerosis
from the Glu C4 and Gln C4 resonances only (65).
However, when label incorporation is measured into
only one or two positions, the complexity of cerebral
energy metabolism is likely to result in ambiguous
numerical solutions because four different fluxes were
simultaneously fitted. Consequently, the previous as-
sertion of a very small activity of pyruvate carboxylase
must be considered with caution.
It should be stressed in this context that our model-
ing does not assume that the rate of pyruvate carbox-
ylation must result in a net loss of Gln into the blood-
stream. Because Gln is the single most concentrated
amino acid in the cerebrospinal fluid, it can be metab-
olized by many other reactions and compartments.
Regardless of the specific quantitative value of pyru-
vate carboxylation, the consistent observation that iso-
topomers of Glu and Gln are not identical suggests that
the Glu/Gln interconversion is not the sole source of
flux through glutamine synthetase, in that pyruvate
carboxylation can contribute substantially to the label-
ing pattern in glial Gln. In fact, our study suggests that
the flux from (neuronal) Glu to (glial) Gln is only on the
order of 41 6 14% of the oxidative glucose consump-
tion, which is much lower than the 1:1 stoichiometric
relationship that has been claimed on the basis of
analysis of C4 time courses only in whole rat head
studies (67). It should also be emphasized that pyru-
vate carboxylation that leads to net formation of Glu,
and eventually Gln, is energetically favorable, because
each Gln molecule synthesized from glucose via pyru-
vate carboxylase (one-half of the glucose is used in the
form of pyruvate for formation of OAA; the other one-
half is used for the formation of acetyl-CoA needed for
the net formation of citrate required to generate the
extra OG required for the net synthesis of Gln) gener-
ates a total of 4 NADH molecules (two are produced by
glycolysis, one by pyruvate dehydrogenase, and one by
isocitrate dehydrogenase, and two ATP are formed by
glycolysis and two are used by PC and glutamine
synthetase), resulting in a net formation of ;10 ATP
molecules (assuming a P/O ratio of 2.5), thereby remov-
ing two NH4
1, which is an energetically highly favor-
able reaction compared with the purely anaerobic com-
bustion of glucose. Including the glial TCA cycle flux of
Vg 5 0.06 mmol zg
21 zmin21 (Table 2), we calculate an
oxidative ATP production of Vg 3 32 1 VPC 3 10, which
represents 87 6 5% of the glial ATP generation, be-
cause the term CMRGlc 3 2 is added when we assume
that all of the glycolysis is confined to the glial com-
partment. This calculation results in 3 mmol zg21 z
min21 of ATP produced in the glial compartment, a
rate that can easily sustain the energy requirements
for maintaining glutamatergic neurotransmission by
removal of extracellular Glu via energy-dependent Glu
transporters (39), because the VNT of 0.17 mmol zg
21 z
min21 (Table 2) requires ;0.35 mmol zg21 zmin21 of
ATP for glutamine synthetase and the Na-K pump. An
important consequence of the measured energetics is
that it underlines the importance of coupled glial en-
ergy metabolism to that in neurons, as previously
pointed out by Magistretti et al. (39). However, it also
stresses the importance of oxidative metabolism, in
that even minor fluxes in oxidative glucose combustion
can easily produce more ATP than the much larger flux
through glycolysis, even in glia (18).
In neurons, if glial lactate is assumed to be the major
energy source, the rate of neuronal ATP generation
(i.e., 30 3 VPDH) is 17 mmol zg
21 zmin21, suggesting
that, although glial oxygen consumption is significant,
it is a minor component of total brain oxygen consump-
tion, contributing one-fifth to one-seventh of the oxy-
gen consumption measured by 13C MRS.
Table 3. Average normalized covariance matrix for fluxes derived in Table 2
VNT Vout Vg VPC VPDH Vx
1.00 20.0960.12 20.3560.18 20.2760.18 0.3160.15 0.2760.11
1.00 0.3860.17 0.3960.14 0.5260.26 20.3260.17
1.00 0.7960.03 20.5460.15 20.5460.10
1.00 20.3960.24 20.2760.34
1.00 20.2560.26
1.00
Table 4. Relative label incorporation into Gln relative
to Glu at the respective position
C2 C3 C4
Gln/Glu 0.4160.02 0.2860.04* 0.3060.01*
Values are means 6 SE; n 5 6. *P , 0.01 vs. ratio measured at
the C2 position.
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Ideally, it is desirable to have a sufficiently large
metabolic pool directly associated with the metabolic
reactions, as is the case, e.g., for lactate in tumors (69).
In the case of the TCA cycle, however, it appears that
mitochondrial TCA cycle intermediates are below de-
tectability in vivo. This requires the detection of iso-
tope kinetics via the amino acids, which are in ex-
change with the TCA cycle intermediates. Of critical
importance in this regard is the delay by which the
isotope labeling kinetics of the (cytosolic) amino acid
lag behind those of the associated (mitochondrial) TCA
intermediate. Consider, for instance, the two pairs
OAA/Asp and OG/Glu: it is clear that the rate of ex-
change Vx relative to the pool size dictates to what
extent the isotope kinetics in the amino acid reflect
those of the associated intermediate. Hence, for a given
Vx, Asp kinetics approximate those of OAA approxi-
mately four times faster than the kinetics of Glu mimic
those of OG (Fig. 3B) because of the approximately
fourfold lower Asp pool size.
Previous studies have focused on the question of
whether the rate of label exchange between cytosolic
Glu and mitochondrial OG is fast compared with the
TCA cycle rate, VPDH (44, 45, 66, 76). In the heart, this
ratio was shown to vary and to be closer to 1 (66, 76).
This appears also to be the case in skeletal muscle (30).
In contrast, a report in brain estimated Vx at 57
mmol zg21 zmin21 (44, 45). Such a high rate of exchange
of negatively charged OG or Glu represents a rather
high rate of exchange of ions that must occur in the
presence of the electrochemical gradient.
Our exchange rates are clearly lower than those
reported in Refs. 44 and 45, which were based on early
studies performed in the late 1980s and early 1990s.
For example, the measurements were performed in
large volumes encompassing a significant fraction of
the brain. Because of the complexity of the modeling
and scarcity of experimental detail in these early stud-
ies and differences in modeling, it is difficult to pin-
point exactly the reason why our results are much
lower. The early modeling studies in brain apparently
did not involve simultaneous fitting of all measured
time courses, as judged from the absence of a covari-
ance matrix or discussion thereof, and from the ab-
sence of a described total cost function. Furthermore,
the sensitivity of the TCA cycle flux on the precise
value of Vx has not been reported in brain. As pointed
out by others (76), the assessment of Vx from Glu
results in a large covariance between VPDH and Vx, and
this covariance may have contributed to some numer-
ical inaccuracy. In contrast, our simulations shown in
Table 1 suggest that the measurement of Asp-labeling
kinetics alone can greatly reduce the influence of Vx on
the measured TCA cycle rate. Therefore, the measure-
ment of Asp kinetics allows in the fitting process a
rather robust measurement of the TCA cycle rate,
which (once known) allows a more precise measure-
ment of Vx. A similar approach has been applied in the
heart, where oxygen consumption measurements were
combined with Glu turnover to achieve excellent quan-
tification of Vx by elimination of the large numerical
covariance (76), whereas in Refs. 44 and 45, the re-
ported errors in Vx are high.
The exchange between OG and Glu on one hand and
between Asp and OAA on the other hand is also an
integral component of the malate-aspartate shuttle,
which transports the two NADH produced by oxidative
glycolysis into the mitochondrion to maintain the cyto-
solic redox potential (Fig. 3B). Therefore Vx cannot be
smaller than VPDH, inasmuch as the glycerol phos-
phate shuttle plays a quantitatively minor role in
maintaining the cytosolic redox potential in brain.
Therefore, the TCA cycle rate was assumed to provide
a lower limit for the exchange rate Vx (Fig. 1B). We also
used the fact that isotope kinetics in a detected amino
acid mimic the isotope kinetics in the corresponding
TCA cycle intermediate much better if the pool size is
reduced, as illustrated in Fig. 3A. Therefore, we also
incorporated Asp labeling in our analysis, in addition
to Glu and Gln. The resulting exchange rate had a
skewed error distribution to higher values but was
statistically not different from the theoretical mini-
Table 5. Sensitivity of VNT, CMRGlc(ox), VG, VPDH, and VPC on the assumed cellular distribution of glutamate
a* VPDH CMRGlc(ox) VNT VPC Vg
0.033 0.6060.06 0.4160.03 0.2560.07 0.0960.02 0.0360.04
0.1 0.5860.06 0.4160.03 0.2060.06 0.0960.02 0.0560.04
0.2 0.5460.06 0.4160.03 0.1460.04 0.0960.02 0.0860.04
0.3 0.4860.06 0.4060.03 0.0960.04 0.1060.02 0.1360.05
0.5 0.3760.06 0.4160.03 0.0560.04 0.1160.02 0.2260.06
Fluxes are expressed in mmol zg21 zmin21 and shown as means 6 SE. *Glu(g) 5 aGlutot, Glu
(n) 5 (1 2 a)Glutot, where Glutot 5 Glu
(g) 1
Glu(n).
Table 6. Sensitivity of VPDH, VNT, CMRGlc(ox), VG, and VPC to the assumed cellular distribution of glutamine
b* VPDH CMRGlc(ox) VNT VPC Vg
0.033 0.6160.07 0.4360.04 0.2560.07 0.09960.02 0.0560.05
0.25 0.6260.07 0.4360.04 0.2560.07 0.09960.02 0.0460.05
0.5 0.6360.07 0.4460.05 0.2560.07 0.10060.02 0.0560.05
Values are means 6 SE expressed in mmol zg21 zmin21. *Gln(n) 5 bGlntot, Gln
(g) 5 Gln(n).
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mum afforded by VPDH. A low rate of exchange between
OG and Glu on the order of the flux through pyruvate
dehydrogenase implies that the malate-aspartate shut-
tle is a substantial mechanism by which label is ex-
changed between the cytosolic amino acids Glu and
Asp and their metabolic partners in the TCA cycle.
This points to the potential that the rate of exchange
between Glu and OG can change under widely varying
metabolic conditions and thus cannot a priori be as-
sumed to be at a constant high level.
Recently, it has been postulated that the rate of
glutamatergic action, assumed to correspond to the
rate of neuronal Glu uptake into glia and interconver-
sion to Gln (also termed the glutamate-glutamine “cy-
cle”) is stoichiometrically related to the oxidative glu-
cose consumption, CMRGlc(ox). In our study, this ratio
was found to be substantially lower than the 1:1 ratio
reported in rat brain (57, 67). The differences can
potentially be ascribed to two assumptions in that
study, namely that turnover of Glu C4 was assumed to
represent total CMRGlc(ox) and turnover of Gln C4 was
assumed to represent exclusively the glutamate-glu-
tamine “cycle.” Indeed, in our study we find that when
the flux through glutamine synthetase, Vsyn, was cor-
related with the oxidative glucose consumption,
CMRGlc(ox), a ratio of 0.8 6 0.2 was calculated that is
much closer to the reported relative rates. However,
the contribution of pyruvate carboxylase needs to be
subtracted from the flux through glutamine syn-
thetase, resulting in a substantial reduction of this
ratio. In this calculation, it should be noted that non-
oxidative contributions to the overall flux through hex-
okinase, glycogen metabolism (13), as well as metabo-
lism of GABAergic neurons, have not been taken into
account, which would lead to an even larger discrep-
ancy between the ATP produced by the glial compart-
ment and the ATP required for the Glu-Gln cycle.
Furthermore, it has been shown that astrocytes can
increase their oxygen consumption after glutamate up-
take (18). Nevertheless, it is quite possible that some
form of monotonic relationship exists between energy
metabolism and glutamatergic action, yet the precise
relationship still remains to be fully characterized.
The presented results can depend on the assumed
distribution of glutamate between the glial and neuro-
nal compartments. For example, the assumed intercel-
lular distribution of glutamate has a strong effect on
the calculated rates (Table 5). The parameter that was
systematically varied was a, which was defined
through the following relationships: Glu(g) 5 aGlutot,
Glu(n) 5 (1 2 aGlutot), where Glutot 5 Glu
(g) 1 Glu(n).
Likewise, the effect of changing the cellular distribu-
tion of glutamine was shown by varying the parameter
b, defined by the relationships Gln(n) 5 bGlntot,
Gln(g) 5 (1 2 bGlntot), where Glntot 5 Gln
(g) 1 Gln(n),
which was without effect on the modeling (Table 6).
However, even the assumption that all but 3.3% of the
metabolic glutamate pool is in neurons does not affect
our suggestion that the relationship between glutama-
tergic action and glucose consumption is not stoichio-
metric, because this relationship increased only to
;0.6, oxidative generation of ATP in astrocytes de-
creased to ;82%, and glial relative to neuronal ATP
generation was reduced to ;10%. Interestingly, in all
simulations, the total oxidative glucose consumption
remains a very stable measurement. The proposed
modeling is subject to further refinement, but we think
we have attempted the most complete modeling with
the least number of assumptions to date. Our study,
therefore, underlines the importance of making such
assumptions in modeling complex biological data, and
the recognition that previous models based on simpler
data need to be considered with appropriate caution.
We conclude that pyruvate carboxylation may be a
significant contributor to the flux though glutamine
synthetase in the human brain in vivo. Glutamatergic
action contributes to the flux through glutamine syn-
thetase, but we conclude that, at rest, oxidative glucose
consumption is not necessarily 1:1 stoichiometrically
correlated with glutamatergic action. Finally, we con-
clude that the exchange of label between 2-oxogluta-
rate and glutamate may be affected by the cellular
energy status.
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